Does Cigna Cover Weight Loss Treatment in New Hampshire? A 2026 Guide

Last updated: July 19, 2026

If you have Cigna insurance in New Hampshire and you’re exploring weight loss treatment options, understanding your plan’s coverage can save you time, money, and frustration. Cigna commercial plans in New Hampshire are administered through Express Scripts (ESI) as the pharmacy benefit manager (PBM), and the ESI formulary includes Zepbound (tirzepatide) at Tier 3. 4. A key point for NH members, since Zepbound was never removed from the ESI formulary, unlike CVS/Caremark (which removed and then reinstated it effective October 1, 2026).

This guide covers what Cigna may cover for weight loss in New Hampshire, how ESI’s 2026 formulary handles GLP-1s and other weight loss medications, New Hampshire’s Electronic Prescribing for Controlled Substances (EPCS) rules under RSA 318-B:21-a as they apply to weight loss drugs, and how to verify your specific benefits before starting treatment.

Coverage varies by plan. This page provides general guidance based on publicly available Cigna and ESI formulary information for 2026. Always verify your specific benefits by calling Cigna at 1-800-244-6224 or checking myCigna.com before booking an appointment.

See If Klarity May Help With Your Weight Loss Goals →

Does Cigna Cover Weight Loss Treatment in New Hampshire?

Cigna commercial plans sold in New Hampshire may cover weight loss treatment, but coverage depends heavily on your specific plan (fully insured vs. self-funded), your employer’s benefit design, and whether the treatment meets Cigna’s medical necessity criteria. Key points for 2026:

• Pharmacy benefit (PBM: Express Scripts/ESI): Weight loss medications such as Wegovy, Zepbound, Saxenda, Contrave, orlistat, phentermine, and Qsymia are processed through ESI. Zepbound remains on the ESI commercial formulary at Tier 3. 4 and was never removed. A meaningful distinction from some other PBMs.
• Medical benefit: Behavioral weight management counseling, nutritional therapy, and bariatric surgery (if medically indicated) may be covered under your medical benefit separately from the pharmacy benefit.
• PA requirements: GLP-1 receptor agonists and other high-tier weight loss medications typically require prior authorization (PA) from ESI based on BMI criteria and documentation of prior behavioral interventions.
• IP0477 does NOT apply to weight loss medications: Cigna’s prior authorization policy IP0477 (effective May 15, 2026) applies exclusively to ADHD stimulant medications. Weight loss medications follow standard ESI formulary PA rules and are not subject to IP0477.
• State parity law (RSA 417-E:1) does NOT govern weight loss: New Hampshire’s mental health and substance use disorder parity law applies only to behavioral health conditions. Weight loss coverage is governed by ACA Essential Health Benefits (EHB) requirements and, for self-funded plans, by ERISA. Not by RSA 417-E:1.

Key facts for Cigna NH weight loss coverage (2026):

• PBM: Express Scripts (ESI)
• Zepbound: Tier 3. 4. NOT removed from ESI formulary
• Wegovy: Tier 3. 4, PA required (BMI ≥30 or ≥27 + comorbidity)
• Phentermine / Qsymia: Schedule IV. EPCS REQUIRED in NH under RSA 318-B:21-a
• GLP-1s / Contrave / orlistat: Non-scheduled. EPCS inapplicable
• IP0477: Does NOT apply to weight loss medications
• Medicare GLP-1 Bridge ($50/month): MA plans only. NOT applicable to Cigna commercial
• State parity (RSA 417-E:1): MH/SUD only. Does NOT govern weight loss
• NH EPCS statute: RSA 318-B:21-a (Schedule II. V, broad)

ESI Formulary for Weight Loss Medications. New Hampshire 2026

The table below summarizes how Express Scripts (ESI) typically covers weight loss medications on its 2026 commercial formulary, along with New Hampshire EPCS status under RSA 318-B:21-a.

Tier placements and PA requirements reflect publicly available ESI commercial formulary data for 2026 and may vary by employer plan design. Always verify with ESI at 1-800-835-3784 or through myCigna.com.

Zepbound and Cigna/ESI: What NH Members Need to Know in 2026

One of the most important points for New Hampshire Cigna members pursuing weight loss treatment in 2026 is that Zepbound (tirzepatide) was never removed from the Express Scripts commercial formulary. This distinguishes ESI. Cigna’s PBM. From CVS/Caremark, which removed Zepbound from its commercial formularies and only reinstated it effective October 1, 2026.

For ESI/Cigna members in New Hampshire:

• Zepbound remains at Tier 3. 4 on the ESI commercial formulary throughout 2026.
• PA is typically required and criteria generally include: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea).
• Documentation of prior behavioral weight management efforts may be required.
• Step therapy may apply. Some plans require trialing another covered medication before approving a GLP-1.
• Wegovy (semaglutide injection) also remains at Tier 3. 4 with PA required under similar criteria.

If you have Cigna through your employer, your plan may be self-funded. Self-funded ERISA plans can opt out of covering weight loss medications entirely, so verifying your specific plan document is essential before starting treatment.

IP0477 and Weight Loss: Cigna’s Stimulant PA Policy Does Not Apply

Since May 15, 2026, Cigna has required prior authorization for all ADHD stimulant medications through policy IP0477. Including generic stimulants that previously did not require PA. This policy change has received significant attention among Cigna members.

IP0477 does not apply to weight loss medications. It is a stimulant-specific PA policy. Weight loss medications. Including GLP-1s, Contrave, phentermine, Qsymia, and orlistat. Are governed by standard ESI formulary PA rules, not by IP0477. If you have seen references to IP0477 and are concerned about your weight loss medication coverage, that policy does not affect your weight loss prescriptions.

New Hampshire EPCS Requirements for Weight Loss Medications

New Hampshire’s Electronic Prescribing for Controlled Substances law (RSA 318-B:21-a) is notably broader than the federal baseline (21 C.F.R. § 456.44) and many other states. While federal law and most state EPCS mandates cover only Schedule II controlled substances, NH RSA 318-B:21-a covers Schedule II through Schedule V.

How this affects weight loss prescriptions in New Hampshire:

• GLP-1 receptor agonists (Wegovy, Zepbound, Saxenda, Foundayo): Not controlled substances under federal or NH law. EPCS entirely inapplicable.
• Contrave (naltrexone/bupropion): Not a controlled substance. EPCS inapplicable.
• Orlistat / Xenical: Not a controlled substance. EPCS inapplicable.
• Phentermine (generic): Schedule IV controlled substance. EPCS REQUIRED in NH under RSA 318-B:21-a.
• Qsymia (phentermine/topiramate ER): Schedule IV controlled substance (driven by phentermine component). EPCS REQUIRED in NH under RSA 318-B:21-a. Also subject to REMS program.

In practical terms: if your Cigna-covered provider prescribes phentermine or Qsymia in New Hampshire, the prescription must be transmitted electronically. Paper prescriptions and call-in prescriptions are not permitted (absent a documented exemption). This is a meaningful operational difference from states like Hawaii, where Schedule IV substances are not subject to EPCS.

NH vs. Other States: EPCS for Weight Loss Medications

Medicare GLP-1 Bridge: Not Applicable to Cigna Commercial Plans in NH

As of July 1, 2026, CMS launched a Medicare GLP-1 Bridge program providing eligible Medicare Advantage and Part D enrollees access to Wegovy, Zepbound, and Foundayo at approximately $50/month. This program has received widespread media coverage.

This program does not apply to Cigna commercial insurance plans in New Hampshire. The Medicare GLP-1 Bridge is a CMS program for Medicare beneficiaries. It is not available to commercially insured individuals under age 65. If you have Cigna through your employer or through the individual/ACA marketplace, your weight loss medication coverage is governed by the ESI commercial formulary, not by the Medicare GLP-1 Bridge.

If you are approaching Medicare eligibility and expect to transition to a Medicare Advantage plan, the CMS Bridge program may become relevant to your weight loss coverage at that time.

New Hampshire Parity Law (RSA 417-E:1) and Weight Loss Coverage

New Hampshire’s mental health and substance use disorder parity law (RSA 417-E:1) requires that fully insured commercial health plans provide coverage for mental health and substance use disorder benefits that is no more restrictive than coverage for comparable medical or surgical conditions. This law is a meaningful protection for behavioral health coverage in NH.

RSA 417-E:1 does not govern weight loss treatment coverage. Weight loss is not a mental health or substance use disorder condition under the parity law’s scope. Coverage for weight loss medications and behavioral weight management programs is governed by:

• ACA Essential Health Benefits (EHB): Preventive services (including behavioral counseling for obesity in adults with a BMI ≥30) may be covered as preventive care under the ACA with no cost-sharing for in-network providers.
• ERISA: Self-funded employer plans are subject to federal ERISA rules, not NH state insurance mandates, and may choose their own benefit designs.
• Your specific plan document: The Summary of Benefits and Coverage (SBC) and Evidence of Coverage (EOC) for your specific Cigna plan define actual weight loss coverage limits.

Prior Authorization for Weight Loss Medications: How the Process Works

If your provider determines a weight loss medication is medically appropriate, here is how the ESI/Cigna PA process typically works for NH members:

1. Provider submits PA request: Your prescribing provider submits the PA through the Availity portal (availity.com) or via fax to ESI. The request must include your BMI, comorbidities (if applicable), and documentation of prior behavioral weight management efforts.
2. ESI reviews within standard timelines: Non-urgent PA decisions are typically made within 72 hours; urgent requests within 24 hours under NH Insurance Department requirements.
3. PA approved or denied: If approved, the medication is covered at the applicable tier copay. If denied, your provider receives a written explanation and information about the appeals process.
4. Level I appeal: You or your provider may appeal to Cigna within 180 days of the denial. Cigna must respond within 30 days for non-urgent pre-service appeals.
5. Level II / External appeal: If the internal appeal is denied, you may request an external independent review through the NH Insurance Department (1-800-852-3416).

For step therapy requirements: some Cigna plans require documentation that you have tried and had an inadequate response to a lower-tier weight loss medication before a GLP-1 will be approved.

What Weight Loss Treatments May Be Covered by Cigna in NH?

Beyond prescription medications, Cigna commercial plans in New Hampshire may cover the following weight loss services (subject to your specific plan):

• Preventive behavioral counseling: Under ACA Section 2713, high-intensity behavioral counseling for adults with a BMI ≥30 is typically covered at no cost-sharing for in-network preventive services.
• Nutritional counseling: Medical nutrition therapy (MNT) with a registered dietitian may be covered when medically indicated, particularly for members with obesity-related comorbidities.
• Telehealth weight management: NH RSA 415-J:2 requires telehealth parity for fully insured commercial plans. Weight management and medication management visits via telehealth may be reimbursed at the same rate as in-person visits.
• Bariatric surgery evaluation and surgery: If you have severe obesity (BMI ≥40, or BMI ≥35 with serious comorbidities), bariatric surgery referral and surgery may be covered under your medical benefit after meeting criteria (usually 6 months of supervised weight management documentation).
• Ongoing monitoring: Lab work, metabolic panels, and follow-up visits related to weight management may be covered under your medical benefit.

Medical Criteria That May Support Coverage

Cigna and ESI typically evaluate PA requests for weight loss medications based on documented medical necessity. Supporting criteria may include:

• Body mass index (BMI) ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity
• Comorbidities commonly recognized: type 2 diabetes (E11), hypertension (I10), dyslipidemia (E78.5), obstructive sleep apnea (G47.33), non-alcoholic fatty liver disease (K76.0)
• Documentation of prior participation in behavioral weight loss program (typically 3. 6 months)
• Medical documentation from a licensed provider confirming diagnosis and treatment necessity
• For Qsymia: enrollment in the REMS program is required prior to dispensing

How to Verify Your Cigna Weight Loss Benefits in New Hampshire

Before scheduling an appointment or starting a weight loss program, follow these steps to verify your benefits:

1. Log in to myCigna.com and search for weight loss medications in the drug cost estimator tool. Confirm whether your specific plan covers GLP-1s or other weight loss drugs.
2. Call Cigna member services at 1-800-244-6224. Ask specifically: “Does my plan cover GLP-1 medications for weight loss? Is PA required? Is there a step therapy requirement?”
3. Call ESI at 1-800-835-3784 to confirm the specific formulary tier, PA requirements, and quantity limits for the medication your provider has recommended.
4. Ask your provider to check your benefits through the Availity portal before submitting a PA to avoid delays.
5. Review your Summary of Benefits and Coverage (SBC). This document outlines what your plan covers and any exclusions. If your plan excludes weight loss medications, the SBC will state this explicitly.

How Klarity Health Can Help

Klarity Health’s network includes 2,000+ licensed providers across New Hampshire and other states who offer telehealth-based weight loss treatment and medication management. Our providers can evaluate whether weight loss medication may be appropriate for you, submit prior authorization requests on your behalf, and work with your Cigna plan throughout the PA process.

Because NH RSA 415-J:2 requires telehealth parity for fully insured Cigna plans in New Hampshire, your telehealth visits with a Klarity provider may be covered at the same cost-sharing level as in-person visits. Verify your specific telehealth benefits with Cigna before booking.

Check If You May Qualify for Weight Loss Treatment →

Frequently Asked Questions

Does Cigna cover Zepbound for weight loss in New Hampshire?

Zepbound (tirzepatide) remains on the ESI commercial formulary at Tier 3. 4 for Cigna members in New Hampshire. Unlike some other PBMs, ESI never removed Zepbound from its formulary. Prior authorization is typically required based on BMI and medical necessity criteria. Coverage depends on your specific employer plan design, as self-funded ERISA plans may exclude weight loss medications.

Does Cigna’s IP0477 policy affect weight loss medications?

No. Cigna’s prior authorization policy IP0477 (effective May 15, 2026) applies exclusively to ADHD stimulant medications. Weight loss medications. Including GLP-1s, Contrave, phentermine, Qsymia, and orlistat. Are not subject to IP0477 and follow standard ESI formulary PA rules.

Do I need an electronic prescription for weight loss medications in New Hampshire?

It depends on the medication. GLP-1 receptor agonists (Wegovy, Zepbound, Saxenda, Foundayo), Contrave, and orlistat are not controlled substances, so New Hampshire’s EPCS law (RSA 318-B:21-a) does not apply. However, phentermine (Schedule IV) and Qsymia (Schedule IV) do require electronic prescribing in NH. Paper or call-in prescriptions for these drugs are not permitted absent a specific exemption.

Can I get the Medicare GLP-1 Bridge program through my Cigna commercial plan?

No. The Medicare GLP-1 Bridge ($50/month for Wegovy, Zepbound, and Foundayo via CMS, effective July 1, 2026) is available only to Medicare Advantage and Part D enrollees. Cigna commercial insurance members in New Hampshire are not eligible for the CMS Bridge program. Your weight loss medication coverage is governed by the ESI commercial formulary.

Does New Hampshire’s mental health parity law (RSA 417-E:1) require coverage of weight loss medications?

No. RSA 417-E:1 applies only to mental health and substance use disorder benefits. Weight loss treatment is not covered by this parity statute. Your weight loss coverage depends on your specific plan’s benefit design, ACA EHB requirements, and. For self-funded employer plans. ERISA.

What if my Cigna plan denies coverage for a weight loss medication?

You have the right to appeal. Submit a Level I internal appeal to Cigna within 180 days of the denial. If the internal appeal is denied, you may request external independent review through the NH Insurance Department at 1-800-852-3416. Ask your provider to submit a letter of medical necessity supporting the appeal with documented comorbidities and BMI data.

Contact Information

• Cigna Member Services: 1-800-244-6224 | myCigna.com
• Express Scripts (ESI) Pharmacy: 1-800-835-3784 | express-scripts.com
• NH Insurance Department (complaints and external appeals): 1-800-852-3416 | nh.gov/insurance
• Klarity Health (weight loss telehealth): helloklarity.com/service/weight-loss

Disclaimer: This page provides general educational information based on publicly available Cigna and ESI formulary data for 2026. Coverage varies by plan, employer benefit design, and individual circumstances. This content does not constitute medical advice, legal advice, or insurance advice. Always verify your specific benefits directly with Cigna (1-800-244-6224) and ESI (1-800-835-3784) before beginning any treatment. Klarity Health providers can help determine if treatment may be appropriate for you, but cannot guarantee insurance coverage.